FDA Office of Hematology and Oncology Products is now Office of Oncologic Diseases November 08, 2019Vol.45 No.42By Matthew Bin Han Ong
Sharpless returns to NCI; Hahn to be nominated FDA commissioner; Giroir assumes acting role November 08, 2019Vol.45 No.42By Alexandria Carolan
Texas votes to keep CPRIT open with another $3 billion in state funding November 08, 2019Vol.45 No.42By Matthew Bin Han Ong
Conversation with The Cancer Letter Purdue’s Thompson: Lomustine establishes proof of principle for resolving cancer drug shortages November 08, 2019Vol.45 No.42By Paul Goldberg
Lomustine’s path from unavailable but cheap to plentiful but expensiveNeeded: A better manufacturing method November 08, 2019Vol.45 No.42By Paul Goldberg
Free Sharpless to return to NCI as Hahn gets nominated as FDA commissioner, with Giroir to serve as acting November 01, 2019Vol.45 No.41By Alexandria Carolan
Free Added indignity: NIH labels Fisher’s papers as “SCIENTIFIC MISCONDUCT” November 01, 2019Vol.45 No.41By Paul Goldberg
Aberle, DuBois, Gupta, Jaffee, Mardis among new members of the National Academy of Medicine October 25, 2019Vol.45 No.40
